Here’s the latest company planning for gene-edited babies The news: A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create ...
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...
Innovation is never easy. It requires the audacity to create a new path, one where we will encounter novel obstacles that demand both resourcefulness and bold imagination. But when we stand together, ...
Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...
A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...
If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...
Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell ...
According to Bloomberg News, Vinay Prasad, who oversees gene therapies at the FDA, said the plans will be published in early November. He foresees the approach sparking curiosity for the next wave of ...
Investors want their money to grow in some shape, form, or fashion with every stock they buy. However, I understand that ...
CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a natural defense system in bacteria that scientists have adapted into a powerful gene-editing tool. This ...
Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback